

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Statement of Results status for the study	
Name of Company: GlaxoSmithKline	
Study No: ING114916 (EudraCT#2011-001646-16)	
Product: GSK1349572	
Title: A Dolutegravir Open Label Protocol for HIV infected, Adult and Adolescent Patients with Integrase Resistance	
Phase: N/A	
Study Period: June 2012 to September 2016	
Centers: 80	
Number of Subjects: 216	
Publications: NA	
Statement on results availability: This is an Expanded Access Program with limited safety follow-up for regulatory purposes. No formal study report was created for this program and thus no results summary is envisaged.	